Antiepileptic drugs and liver disease

Seizure

Volumn 15, Issue 3, 2006, Pages 156-164

  Ahmed, Syed Nizamuddin ^a   Siddiqi, Zaeem A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiepileptic drugs; Epilepsy; Hepatotoxicity; Liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APLASTIC ANEMIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; EDEMA; EOSINOPHILIA; EPILEPSY; FATTY LIVER; GRANULOMATOUS HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERTHERMIA; IMMUNOPATHOLOGY; JAUNDICE; LEUKOCYTOSIS; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LYMPHADENOPATHY; MOOD DISORDER; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RHABDOMYOLYSIS; SPEECH DISORDER; VOMITING;

ANTICONVULSANTS; BIOTRANSFORMATION; HUMANS; LIVER; LIVER DISEASES;

EID: 33645020815     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2005.12.009     Document Type: Article

References (97)

1. R.N.H. Pugh I.M. Murray-Lyon J.L. Dawson et. al. Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 649-659
2. K.I. Majeed Hyperammonemia E-medicine 2003
3. M.A. Montenegro C.M. Ferreira F. Cendes M. Li C.A. Guerreiro Clobazam as add-on therapy for temporal lobe epilepsy and hippocampal sclerosis Can J Neurol Sci 32 1 2005 93-96
4. C. O'dell S. Shinnar K.R. Balban-Gil et. al. Rectal diazepam gel in the home management of seizures in children Pediatr Neurol 33 3 2005 166-172
5. J. McIntyre S. Robertson E. Norris et. al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: A randomized controlled trial Lancet 366 9481 2005 205-210
6. G. Brathen E. Ben-Menachem E. Brodtkorb et. al. EFNS guideline on the diagnosis and management of alcohol-related seizures: Report of an EFNS task force Eur J Neurol 12 8 2005 575-581
7. J.C. Brevoord K.F. Joosten W.F. Art R.W. van Rooij M. de Hoog Status epilepticus: Clinical analysis of a treatment protocol based on midazolam and Phenytoin J Child Neurol 20 6 2005 476-481
8. P.B. Andreasen J. Hendel G. Greisen E.F. Hvidberg Pharmacokinetics of diazepam in disordered liver function Eur J Clin Pharmacol 10 1976 115-120
9. H.R. Ochs D.J. Greenblatt B. Eckardt J.S. Harmatz R.I. Shader Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation Clin Pharmacol Ther 33 4 1983 471-476
10. M.H. Adams W.J. Poynor W.R. Garnett et. al. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers Biopharm Drug Dispos 19 8 1998 501-515
11. J.W. Kraus P.V. Desmond J.P. Marshall R.F. Johnson S. Shenker G.R. Wilkinson Effect of aging and liver disease on disposition of lorazepam Clin Pharmacol Ther 24 1978 411-419
12. I. Bernus R.G. Dickinson W.D. Hooper M.J. Eadie Dose-dependent metabolism of carbamazepine in humans Epilepsy Res. 24 1996 163-172
13. K.A. Kim S.O. Oh P.W. Park J.Y. Park Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects Eur J Clin Pharmacol 61 4 2005 275-280
14. R.D. Scheyer J.A. Cramer R.H. Mattson A pharmacodyanamic approach to the estimate of carbamazepine autoinduction J Pharm Sci 83 4 1994 491-494
15. I. Cepelak T.Z. Grubisic A. Mandusic B. Rekic J. Lenicek Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children Clinica Chimica Acta 276 1998 121-127
16. M.S. Benedetti B. Ruty E. Baltes Induction of endogenous pathways by antiepileptics and clinical implications Fundam Clin Pharmacol 19 2005 511-529
17. F.E. Driefus D.H. Langer Hepatic considerations in the use of antiepileptic drugs Epilepsia 28 Suppl. 2 1987 S23-S29
18. G. Hopen I. Nesthus O. Laerum Fatal CBZ associated hepatitis Acta Med Scand 210 1981 333-335
19. J.S. Millership J. Mifsud D. Galea W.C. McRoberts J.T.G. Hamilton Chiral aspects of the human metabolism of ethosuximide Biopharm Drug Dispos 26 2005 225-232
20. J.S. Millership J. Mifsud P.S. Collier The metabolism of ethosuximide Eur J Drug Metab Pharmacokinet 18 4 1993 349-353
21. A.E. Bryant III F.E. Dreifuss Hepatotoxicity associated with antiepileptic drug therapy CNS Drugs 4 2 1995 99-113
22. D.L. Coulter Ethosuximide-induced liver dysfunction Arch Neurol 40 6 1983 393-394
23. J.M. Pellock J.L. Perhach R.D. Sofia Felbamate R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic drugs 5th ed. 2002 Raven Press New York 301-318
24. J. French M. Smith E. Faught L. Brown Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy Neurology 52 1999 1540-1545
25. A.F. Cohen G.S. Land D.D. Breimer W.C. Yuen et. al. Lamotrigine a new anticonvulsant: Pharmacokinetics in normal humans Clin Pharmacol Ther 42 1987 535-541
26. P. Marcellin F. de Bony C. Garret et. al. Influence of cirrhosis on lamotrigine pharmacokinetics Br J Clin Pharmacol 51 5 2001 410-414
27. V. Furlan S. Demirdjian O. Bourdon et. al. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers J Pharmacol Exp Ther 289 2 1999 1169-1175
28. A.J. Makin S. Fitts R. Williams et. al. Fulminant hepatic failure induced by lamotrigine [letter] BMJ 311 1995 292
29. G. Sauve S. Bresson-Hadni P. Prost et. al. Acute hepatitis after lamotrigine administration Dig Dis Sci 45 2000 1874-1877
30. R. Arnon D. DeVivo A.R. Defelice et. al. Acute hepatic failure in a child treated with lamotrigine Pediatr Neurol 18 1998 251-252
31. M. Fayad R. Choueiri M. Mikati Potential hepatotoxicity of lamotrigine Pediatr Neurol 22 2000 49-52
32. T.W. May E. Korn-Merker B. Rambeck Clinical pharmacokinetics of oxcarbazepine Clin Pharmacokinet 42 12 2003 1023-1042
33. M. Bialer Oxcarbazepine; chemistry, biotransformation, and pharmacokinetics R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic drugs 5th ed. 2002 Raven Press New York 459-465
34. E. Bosdure A. Cano B. Roquelaure et. al. Oxcarbazepine and DRESS syndrome: A pediatric cause of acute liver failure Arch Pediatr 11 9 2004 1073-1077
35. M.L. Friis O. Kristensen J. Boas et. al. Therapeutic experiences with 947 epileptic out-patients in Oxcarbazepine treatment Acta Neurol Scand 87 3 1993 224-227
36. K.J. Reinikainen T. Keranen T. Halonen et. al. Comparison of Oxcarbazepine and Carbamazepine: A double-blind study Epilepsy Res 1 5 1987 284-289
37. P. Kwan M. Brodie Phenobarbital for the treatment of epilepsy in the 21st century: A critical review Epilepsia 45 9 2004 1141-1149
38. J. Alvin T. McHorse A. Hoyumpa M.T. Bush S. Schenker The effect of liver disease in man on the disposition of Phenobarbital J Pharmacol Exp Ther 192 1975 224-235
39. A.M. Li E.A. Nelson E.K. Hon et. al. Hepatic failure in a child with anti-epileptic hypersensitivity syndrome J Paediatr Child Health 41 4 2005 218-220
40. E.A. Roberts S.P. Spielberg M. Doldbach M.J. Philips Phenobarbital hepatotoxicity in an 8-month-old infant J Hepatol 10 2 1990 235-239
41. H.W. Aiges F. Daum M. Olson E. Kahn S. Teichberg The Effects of Phenobarbital and Diphenylhydantoin on liver function and morphology J Pediatr 97 1 1980 22-26
42. P.M. Jeavons Hepatotoxicity of Antiepileptic Drugs J. Oxly D. Janz H. Meinardi Chronic toxicity of antiepileptic drugs 1982 Raven Press NY
43. H.H. Merritt T.J. Putnam Sodium diphenyl hydantoinate in the treatment of convulsive disorders JAMA 111 1938 1068-1073
44. M. Walker Status epilepticus: An evidence based guide BMJ 331 2005 673-677
45. M. Bajpai L.K. Roskos D.D. Shen R.H. Levy Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of Phenytoin to its major metabolite Drug Metab Dispos 24 12 1996 1401-1403
46. H.G. Aldenhovel The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma glutamyl transferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase Eur Arch Psychiatry Neurol Sci 237 5 1988 312-316
47. H. Kazamatsuri Elevated serum alkaline phosphatase levels in epilepsy during diphenylhydantoin therapy N Engl J Med 283 1970 1411-1412
48. G.P. Mendis F.B. Gibberd H.A. Hunt Plasma activities of hepatic enzymes in patients on anticonvulsant therapy Seizure 2 1993 319-323
49. C.L. Harden Therapeutic safety monitoring: What to look for and when to look for it Epilepsia 41 Suppl. 8 2000 S37-S44
50. F.G. Mullick K.G. Ishak Hepatic injury associated with diphenylhydantoin therapy: A clinicopathological cases of 20 cases Am J Clin Pathol 74 1980 442-452
51. S. Craig Phenytoin poisoning Neurocrit Care 3 2 2005 161-170
52. S. Arroyo B.R. Boothman M.J. Brodie J.S. Duncan R. Duncan et. al. A randomized open-label study of tiagabine given two or three times daily in refractory epilepsy Seizure 14 2 2005 81-84
53. E. Ben-Menachem International experience with tiagabine add-on therapy Epilepsia 36 1995 14-21
54. B. Uthman J. Rowan P.A. Ahman et. al. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial Arch Neurol 55 1998 56-62
55. L.E. Gustavson H.B. Mengel Pharmacokinetics of Tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses Epilepsia 36 1995 605-611
56. A.H. Lau L.E. Gustavson R. Sperelakis et. al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic dysfunction Epilepsia 38 1997 445-451
57. R. Kälviäinen Tiagabine: Clinical efficacy and use in epilepsy R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic drugs 5th ed. 2002 Raven Press New York 698-704
58. S. Arroyo W.E. Dodson M.D. Privitera T.A. Glauser Naritoku et. al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy Acta Neurol Scand 112 4 2005 214-222
59. M. Britzi E. Perucca S. Soback R.H. Levy Fattore et. al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine Epilepsia 46 3 2005 378-384
60. TOPAMAX topiramate Tablets and Sprinkle Capsules Product Monograph. JANSSEN-ORTHO Inc. 2001.
61. K. Bjoro L. Gjerstad O. Bentdal et. al. Topiramate and fulminant liver failure Lancet 352 1998 1119
62. R.J. Doan M. Clendenning Topiramate and hepatotoxicity Can J Psychiatry 45 10 2000 937
63. A. Bumb N. Diederich S. Beyenburg Adding topiramate to valproate therapy may cause reversible hepatic failure Epileptic Disord 5 3 2003 157-159
64. D. Schmidt H. Siemes Role of liver function tests in monitoring anticonvulsant use CNS Drugs 10 5 1998 321-328
65. R. Gugler G.E. Von Unruh Clinical pharmakokinetics of valproic acid Clinical Pharmacokinetics 1980 67-83
66. M.D. Sztajnkrycer Valproic acid toxicity: Overview and management J Clin Toxicol 40 6 2002 789-801
67. L.J. Wilmore B.J. Wilder J. Bruni H.J. Vallarreal Effect of valproic acid on hepatic function Neurology 28 1978 961-964
68. B.L. Felker K.L. Sloan J.A. Dominitz R.F. Barnes The safety of valproic acid use for patients with hepatitis C infection Am J Psychiatry 160 2003 174-178
69. E. Hauser R. Siedl M. Freilinger et. al. Hematological manifestations and impaired liver synthetic function during valproate monotherapy Brain Dev 18 1996 105-109
70. M. Giroud P. D'Athis O. Guard et. al. Evaluation of changes in gamma-glutamyltransferase in chronic treatment with antiepileptic agents Pathol Biol (Paris) 33 8 1985 810-818
71. A.R. Riela Recognition of valproate-associated hepatotoxicity R.H. Levy J.K. Penry Antiepileptic drugs 1991 Raven New York 137-142
72. T.P. Bohan E. Helton I. McDonald et. al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity Neurology 56 10 2001 1405-1409
73. F.E. Dreifuss N. Santilli D.H. Langer et. al. Valproic acid hepatic fatalities: II. US experience since 1984 Neurology 1989 39201-40201
74. P. Genton P. Gelisse Valproic acid, adverse effects R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic drugs 2002 Lippincott Williams and Wilkins 837-851
75. F.E. Dreifuss Fatal liver failure in children on valproate Lancet 1 1987 47-48
76. S. Gopaul K. Farrell F. Abott Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (e)-2,4-diene VPA in people with epilepsy taking VPA Epilepsia 44 3 2003 322-328
77. S.A. König M. Schenk C. Sick et. al. Fatal liver failure associated with valproate therapy in a patient with friedreich's disease: Review of valproate hepatotoxicity in adults Epilepsia 40 7 1999 1036-1040
78. M. McCall J.A. Bourgeois Valproic acid-induced hyperammonemia J Clin Psychopharmacol 24 5 2004 521-526
79. F. Eyer N. Felgenhauer K. Gempel et. al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy J Clin Psychopharmacol 25 4 2005 376-380
80. V. Tong W.X. Teng T.K. Chang F.S. Abbott Valproic Acid I: Time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats Toxicol Sci 86 2 2005 427-435
81. V. Tong W.X. Teng T.K. Chang F.S. Abbott Valproic Acid II: Effects of oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes Toxicol Sci 86 2 2005 436-443
82. A.E. Bryant F.E. Dreifuss Valproic acid hepatic fatalities. III. U.S. experience since 1986 Neurology 46 1996 465-469
83. R.E. Appleton D.A. Applegarth J.E. Dimmick et. al. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects Can J Neurol Sci 17 2 1990 145-148
84. K. Ballaban-Gil C. Callahan C. O'Dell et. al. Complication of the ketogenic diet Epilepsia 39 7 1998 744-748
85. D.A. Lyczkowski H.H. Pfeifer S. Ghosh E.A. Thiele Safety and tolerability of the ketogenic diet in pediatric epilepsy: Effects of valproate combination therapy Epilepsia 46 9 2005 1533-1538
86. G.J. Luef M. Waldman W. Sturm et. al. Valproate therapy and nonalcoholic fatty liver disease Ann Neurol 55 5 2004 729-732
87. D.E. Mandelbaum M. Bunch S.L. Kugler A. Venkatasubramanian J.B. Wollack Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy J Child Neurol 20 7 2005 594-597
88. D. Chadwick A. Marson D. Chadwick Zonisamide add-on for drug-resistant partial epilepsy. Zonisamide add-on for drug-resistant partial epilepsy Cochrane Database Syst Rev 4 2005 CD001416
89. I.E. Leppik Zonisamide: Chemistry, mechanism of action, and pharmacokinetics Seizure 135 2004 S5-S9
90. M. Seino T. Okuma M. Miyasaka et. al. Efficacy evaluation of AD-810 (zonisamide): Double-blind study comparing with carbamazepine [in Japanese] J Clin Exp Med 144 1988 275-291
91. M.J. McLean Gabapentin Epilepsia 36 Suppl. 2 1995 S73-S86
92. A. Richens Pharmacology and clinical pharmacology of vigabatrin J Child Neurol 6 1991 2S7-2S10
93. K. Kellermann V. Soditt B. Rambeck O. Klinge Fatal hepatotoxicity in a child treated with vigabatrin Acta Neurologica Scandinavica 93 5 1996 380-381
94. M.C. Walker P.N. Patsalos Clinical pharmacokinetics of new antiepileptic drugs Pharmacol Ther 67 1995 351-384
95. J. Brockmoller T. Thomsen K. Eckl et. al. Leviteracetam: Liver impairment does not influence its pharmacokinetic profile Epilepsia 41 Suppl. 6 2000 150 (abstr)
96. J. Brockmoller T. Thomsen M. Wittstock R. Coupez H. Lochs I. Roots Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): Characterization by dynamic liver function tests Clin Pharmacol Ther 77 6 2005 529-541
97. P. Camfield C. Camfield J. Dooley et. al. Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value CMAJ 140 1989 1303-1305